As shown in Figure 3, this therapy using CBDCA and anti-PD-1 effectively kills the secondary tumor, and maintains sustainable protection, which has been demonstrated as remarkably improved long-term survival rates. The gene discussed is PDCD1; the disease is neoplasm.